DOT drug testing changes effective January 1, 2018

The Department of Transportation (DOT) will now be consistent with other federal testing with expanded opiates added effective January 1, 2018. The DOT is amending its drug-testing program regulation to add hydrocodone, hydromorphone, oxymorphone, and oxycodone to its drug-testing panel; add methylenedioxyamphetamine as an initial test analyte, and remove methylenedioxyethylamphetamine as a confirmatory test analyte.

The revision of the drug-testing panel harmonizes DOT regulations with the revised HHS Mandatory Guidelines established by the U.S. Department of Health and Human Services for Federal drug-testing programs for urine testing. This final rule clarifies certain existing drug-testing program provisions and definitions, makes technical amendments and removes the requirement for employers and Consortium/Third Party Administrators to submit blind specimens.

See Federal Register at:  https://www.federalregister.gov/documents/2017/11/13/2017-24397/procedures-for-transportation-workplace-drug-and-alcohol-testing-programs-addition-of-certain

Recent Stories
CDC Publishes Summary of HAI Prevention Progress in U.S. from 2006-2016

Last Chance to Refer, Still Time to Win Conference Prizes

CDC Health Alert Network (HAN) Health Advisory Regarding Seasonal Influenza A(H3N2) Activity and Antiviral Treatment of Patients with Influenza